BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
First patient dosed at the Emory University School of Medicine in Atlanta, Georgia Trial will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in up to 200 patients ...
Lenzilumab among the promising agents selected for ACTIV program from pool of approximately 400 candidate agents “Lenzilumab is one of the few Phase 3 treatment options in development for COVID-19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results